Free Trial
NASDAQ:DBVT

DBV Technologies (DBVT) Stock Price, News & Analysis

$0.80
-0.01 (-1.23%)
(As of 09/6/2024 ET)
Today's Range
$0.75
$0.92
50-Day Range
$0.75
$1.03
52-Week Range
$0.50
$3.25
Volume
45,184 shs
Average Volume
49,255 shs
Market Capitalization
$77.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

DBV Technologies MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
399.9% Upside
$4.00 Price Target
Short Interest
Healthy
0.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of DBV Technologies in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1,749 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.43) to ($1.09) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.95 out of 5 stars

Medical Sector

343rd out of 910 stocks

Biological Products, Except Diagnostic Industry

51st out of 155 stocks

DBVT stock logo

About DBV Technologies Stock (NASDAQ:DBVT)

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBVT Stock Price History

DBVT Stock News Headlines

StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
DBV Technologies SA (DBV0.SG)
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
DBV Technologies Plans to Change ADS Ratio
See More Headlines
Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/30/2024
Today
9/07/2024
Next Earnings (Estimated)
10/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DBVT
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$5.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+399.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-72,730,000.00
Net Margins
-638.21%
Pretax Margin
-638.16%

Debt

Sales & Book Value

Annual Sales
$15.73 million
Book Value
$0.82 per share

Miscellaneous

Free Float
94,660,000
Market Cap
$77.20 million
Optionable
Optionable
Beta
0.68
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Key Executives

  • Mr. Daniel Tassé (Age 64)
    CEO & Director
    Comp: $1.21M
  • Dr. Pharis Mohideen (Age 59)
    Chief Medical Officer
    Comp: $725.12k
  • Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. (Age 55)
    CFO & Principal Accounting Officer
  • Dr. Kevin P. Malobisky M.S.
    Ph.D., R.A.C., Chief Operations Officer
  • Ms. Michele F. Robertson
    Chief Legal Officer
  • Ms. Caroline Daniere (Age 49)
    Chief Human Resources Officer & Chief of Staff
  • Dr. Wence Agbotounou
    Chief Clinical Trial Officer & Senior VP
  • Mr. Edward P. Jordan M.B.A. (Age 56)
    Senior Vice President of Commercial Operations North America
  • Alan Kerr
    Senior VP & Head of Global Regulatory Affairs
  • Mr. Pascal Wotling
    Chief External Manufacturing & Supply Chain Officer

DBVT Stock Analysis - Frequently Asked Questions

How have DBVT shares performed this year?

DBV Technologies' stock was trading at $1.9056 at the beginning of 2024. Since then, DBVT shares have decreased by 58.0% and is now trading at $0.8001.
View the best growth stocks for 2024 here
.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) issued its quarterly earnings results on Tuesday, July, 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.08. The firm earned $1.16 million during the quarter, compared to analysts' expectations of $1.42 million. DBV Technologies had a negative trailing twelve-month return on equity of 74.41% and a negative net margin of 638.21%.

When did DBV Technologies' stock split?

DBV Technologies's stock reverse split on the morning of Monday, June 3rd 2024. The 1-2 reverse split was announced on Monday, June 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

Who are DBV Technologies' major shareholders?

DBV Technologies' top institutional investors include Point72 Asset Management L.P. (1.61%). Insiders that own company stock include Pharis Mohideen, Timothy E Morris and Adora Ndu.
View institutional ownership trends
.

How do I buy shares of DBV Technologies?

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX) and AbbVie (ABBV).

This page (NASDAQ:DBVT) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners